FYI: The "lifetime use" framing is drug company spin. (And the science is starting to push back.)

Well, we've been told for two years that GLP-1s are lifetime medications because obesity is a chronic disease, and most reasonable people accepted it. Today's issue is the case for why that framing is shakier than the marketing implies, and why the evidence is starting to push back.

This is the first openly contrarian issue Off Label has run. To be clear up front: this is not anti-drug. The drugs work. The benefits are real. The contrarian read is about the "forever" part, which is the most quietly assumed and least examined piece of the entire GLP-1 conversation.

This is Off Label, Not Medical Advice.

Let's go.

The Morning Read: The "lifetime use" framing is drug company spin. The science is more uncertain than the marketing implies.

On April 21, 2026, the Centers for Medicare and Medicaid Services announced it is delaying the Medicare Part D portion of the BALANCE Model, the federal program designed to expand Medicare coverage of GLP-1 drugs in 2027, "pending further evaluation and data collection." The Medicaid component is still launching May 1. The Part D piece, which would have brought tens of millions of seniors onto these drugs at federally-negotiated prices, got hit pause.

You did not see this story dominate the wellness press. You should have.

The reason it matters: if the lifetime-use framing for GLP-1s were as solidly established as the marketing implies, the federal government would be expanding coverage right now, not delaying it. The fiscal math is reshaping the medical conversation, not the other way around. And the fiscal math is brutal.

Each one of those numbers is doing work in this issue. We're going to walk through them.

In March 2025, researchers at the University of Chicago published the most rigorous cost-effectiveness analysis of GLP-1s ever conducted. Hwang, Laiteerapong, Huang, and Kim. JAMA Health Forum. They modeled the lifetime health effects of tirzepatide and semaglutide against older obesity medications using a population of 4,823 NHANES participants representing 126 million eligible US adults.

Their conclusions:

For comparison, naltrexone-bupropion (the older generic combination drug) was cost-saving and had an 89.1% probability of being cost-effective at the $100K threshold.

Read that again. The drugs we're being told are lifetime treatments are wildly cost-ineffective at lifetime use prices, by the most rigorous available analysis. The drug we're rarely told about (a $25/month generic combination) is the one the math actually supports.

The lead author of that study, Dr. David Kim, said the quiet part out loud in a UChicago Medicine interview: "If we don't have to keep everyone on these drugs forever, we can reduce costs significantly."

That is the senior author of the JAMA Health Forum cost-effectiveness paper publicly questioning the lifetime-use framing.

The UK's National Institute for Health and Care Excellence published guidance TA875 in March 2023. Their decision: semaglutide is recommended for NHS weight management, but only for a maximum of 2 years, and only within specialist multidisciplinary services.

Their stated reasoning: the clinical trial evidence base extends to about 2 years. They will not recommend reimbursement beyond what the evidence supports. They added a futility rule too: stop treatment if the patient hasn't lost at least 5% of body weight after 6 months on the maintenance dose.

NICE will review the guidance in 2026 if longer-term evidence emerges. As of right now, that evidence has not emerged.

This is a major Western regulator, in the country that hosts Novo Nordisk's European operations, applying evidence-based medicine and arriving at "2 years, then stop." The same drug in the same year. Different framing.

When American patients are told "this is lifetime treatment for a chronic disease," they are being told something the British regulator does not accept. That is a meaningful gap.

Novo Nordisk spent $485 million on US direct-to-consumer advertising for Wegovy and Ozempic in just the first nine months of 2025, per MediaRadar. Wegovy alone was $316 million, up 54% year-over-year. Ozempic was $169 million, up 44%.

For context, the United States and New Zealand are the only developed countries that allow direct-to-consumer pharmaceutical advertising at all. Novo's $485 million 9-month spend is one of the largest pharma DTC campaigns in obesity medicine history.

The "Believe On" Wegovy campaign, launched in 2024, included taglines emphasizing that "Novo Nordisk are committed to this community for the long term." The "There's Only One Ozempic" campaign launched January 20, 2026 with Justin Long and John Hodgman. Eli Lilly invested heavily in Mounjaro TV ads, including a single "What If" campaign reportedly costing approximately $19.6 million. Lilly's Q2 2025 marketing, selling, and admin expenses hit $2.75 billion, up 30% year-over-year, driven primarily by promotional efforts.

This is the largest sustained investment in shaping patient expectations in the modern obesity-drug era. The framing is not neutral. The framing is the product.

This is documented, not speculative.

Spain (June 2025). Novo Nordisk launched an "Obesity Without Filters" awareness campaign with bus shelter posters claiming "obesity can kill" and a video featuring a young woman pressured to admit obesity is a disease. Spanish health authorities investigated for possible covert prescription-drug advertising. The campaign was pulled. Spain's Secretary of State for Health, Javier Padilla, told Euronews Health pharmaceutical companies are both "creating awareness of the disease and selling the drug to treat it."

Ireland (Spring 2025). Ireland's Health Products Regulatory Authority found Novo Nordisk had broken rules around marketing to healthcare workers over a three-year period.

United Kingdom (2023-2025). The Association of British Pharmaceutical Industry suspended Novo Nordisk's membership for two years over regulatory breaches in marketing to healthcare providers. The membership was reinstated in March 2025.

Three regulators. Two-year span. Same company. Same pattern. None of these are random complaints. They are official findings from national authorities.

When a major drug manufacturer racks up regulatory actions across three countries in a 24-month window, the question becomes whether the underlying messaging strategy is itself problematic. The "obesity is a chronic disease requiring lifetime treatment" frame is the spine of that messaging strategy.

Ozempic was FDA-approved for diabetes in late 2017. About 8 years of real-world data.

Wegovy was approved for weight loss in 2021. About 4 to 5 years.

Tirzepatide (Mounjaro) was approved in 2022. Tirzepatide (Zepbound) for weight loss in 2023.

That is the entire long-term safety database for the GLP-1 class as currently used. The peer-reviewed literature is direct about the gap:

The marketing presents lifetime use as established. The science presents it as unknown.

These are not the same thing.

Three things to take from this.

GLP-1s might genuinely benefit some patients across decades of use. That hypothesis is reasonable. It is also unproven. There is a difference between "best available evidence supports continued use for benefit" and "we know this drug is safe and effective for 30 years." Marketing collapses that distinction. Science doesn't.

The bulk of weight loss happens in the first year. Cardiovascular benefits accrue over 1 to 3 years per the SELECT trial. Most cardiometabolic improvements appear within 1 to 2 years. Years 5, 10, and 20 of GLP-1 use are speculative territory. If most of what you're paying for is captured in years 1 to 3, the math for indefinite use breaks down.

This is not a conspiracy. It is the structure of US obesity medicine. The American Diabetes Association launched the "Obesity Association" in June 2025 with "inaugural support from Novo Nordisk Inc." Speaker fees, advisory board positions, research grants, conference sponsorships, continuing medical education programs, all funded in part by the manufacturers whose drugs the experts then recommend. The framing follows the funding. Both can be true: the experts are credentialed AND the funding shapes the framing.

Text your doctor this: "I keep hearing that GLP-1s are lifetime medications because obesity is a chronic disease. But the longest clinical trials only run about 2 years, the UK NICE guidelines cap treatment at 2 years, and the real-world data shows fewer than 1 in 4 patients stay on them past 1 year. Can we talk about whether 'lifetime' is actually the right framing for me, or whether a 2-year course with a structured maintenance plan would be more evidence-based for my situation?"

Copy, paste, send.

The lifetime-use framing is the foundation of the entire GLP-1 commercial business model. At list prices, lifetime use translates to roughly $400,000 to $700,000 of per-patient revenue across 30 years. Novo Nordisk's and Eli Lilly's stock valuations are built on the assumption that GLP-1 patients become chronic patients. If real-world adherence is fewer than 1 in 4 at 1 year, that thesis is fragile. Investors know it. The companies know it. The marketing is downstream of the math.

Direct-to-consumer pharmaceutical advertising is uniquely American. Almost every other developed country bans it. The framing has more grip in US patient populations than international ones because $485 million in 9 months of advertising creates that grip.

The Obesity Association is funded by Novo Nordisk. Not hidden. Just rarely highlighted. When a Novo-funded medical advocacy division publishes guidance about chronic-disease management of obesity, the funding source is part of the context.

CMS price negotiations are coming. Semaglutide is among the first 15 drugs selected for Medicare price negotiation under the Inflation Reduction Act, with effects starting January 2027. Historical IRA negotiations have produced about 20% price cuts. That gets semaglutide partway to cost-effectiveness but nowhere near the 82% cut Hwang's analysis says it would need.

The patent cliff matters. Semaglutide's US patent expires in 2032. Tirzepatide's expires in 2036. When generics arrive, the math changes completely. A $40/month generic semaglutide is cost-effective at lifetime use. A $969/month branded one is not.

Watch this: the CMS BALANCE Model 80% participation threshold deadline. CMS must announce by April 30, 2026 (next Tuesday) whether enough Medicare Part D plans have applied to participate for 2027 implementation. If the threshold isn't met, BALANCE doesn't launch in Medicare in 2027 at all. Tens of millions of Medicare beneficiaries do not get expanded GLP-1 coverage. If it does launch, it bundles GLP-1 access with mandatory lifestyle program participation, which is itself a contrarian reframe of these drugs as lifestyle adjuncts rather than standalone chronic-disease therapy. Either outcome is the most important real-time obesity-medicine policy event of 2026 and almost no health newsletter is treating it that way.

Tomorrow: We're going inside the work of one of the researchers quietly building a different model for GLP-1 prescribing, the kind that takes the evidence gaps seriously and proposes an alternative to the lifetime-use default.

Hit reply and tell us what you want us to cover. Every reply is read. Story tips: [email protected]

See you in your inbox.

— Off Label

This is Off Label, Not Medical Advice. Content is for informational purposes only. Always consult a qualified healthcare provider before making medical decisions about starting, stopping, or modifying any prescription medication. Off Label is not anti-medication. The drugs discussed in this issue are FDA-approved, clinically effective for their approved indications, and have demonstrated meaningful health benefits in published trials. The thesis of this issue is about the framing of duration of use, not about the validity or utility of the medications themselves.